Keyphrases
Alisertib
50%
Antitumor Effect
30%
Apoptosis
10%
Aurora Kinase A (AURKA)
100%
Aurora Kinase Inhibitor
10%
Caspase-3
10%
CCK-8 Assay
10%
Cell Cycle Arrest
10%
Cell Growth
10%
Cell number
10%
Checkpoint Genes
10%
Cholangiocarcinoma
100%
Cholangiocarcinoma Cell Line
10%
Chromosomal Instability
10%
Different Datasets
10%
Dysregulated
10%
Gene Expression
10%
Human Cholangiocarcinoma
10%
Interacting Proteins
10%
Kinesin
10%
Knockdown
10%
M Phase
10%
Malignancy
10%
Mitotic Checkpoint
10%
Mitotic Spindle Checkpoint
30%
MRNA Expression
10%
Neoplasms
10%
Number Counting
10%
Polo-like Kinase 1 (PLK1)
10%
Poor Outcome
10%
Poor Prognosis
100%
Poor Survival
10%
Public Dataset
10%
Rational Therapeutics
10%
Small Interfering RNA (siRNA)
20%
Specific Inhibitor
10%
Target Molecule
10%
Therapeutic Rationale
100%
Therapeutic Target
10%
TPX2
10%
Tumor Growth
10%
Tumor Progression
10%
Xenograft Model
10%
Xenograft Mouse Model
10%
Xenopus
10%
Medicine and Dentistry
Alisertib
45%
Aurora A Kinase
100%
Cancer
9%
Caspase 3
9%
Cell Cycle Arrest
9%
Cell Cycle Checkpoint
9%
Cell Cycle M Phase
9%
Cell Growth
9%
Cholangiocarcinoma
100%
Cholangiocarcinoma Cell Line
9%
Cholecystokinin Octapeptide
9%
Chromosomal Instability
9%
In Vitro
9%
Kinesin
9%
Messenger RNA
9%
Neoplasm
9%
Polo Like Kinase 1
9%
Programmed Cell Death
9%
Protein Interaction
9%
Small Interfering RNA
18%
Spindle Checkpoint
36%
Targeting Protein
9%
Tumor Progression
18%
Xenograft
18%
Pharmacology, Toxicology and Pharmaceutical Science
Alisertib
45%
Aurora A Kinase
100%
Bile Duct Carcinoma
100%
Caspase 3
9%
Cholecystokinin Octapeptide
9%
Chromosomal Instability
9%
Kinesin
9%
Messenger RNA
9%
Mouse Model
9%
Neoplasm
9%
Polo Like Kinase 1
9%
Small Interfering RNA
18%
Tumor Growth
18%
Xenopus
9%